NHS Branded Medicines Tranche A - London & SOFE & Adult Influenza National
A Contract Award Notice
by NHS ENGLAND
- Source
- Contracts Finder
- Type
- Contract (Products)
- Duration
- 2 year
- Value
- £262M
- Sector
- HEALTH
- Published
- 24 Jul 2025
- Delivery
- 01 Sep 2025 to 31 Aug 2027
- Deadline
- 18 Mar 2025 13:00
Concepts
- runcorn
- pharmaceutical products
- nhs framework agreement
- adult influenza
- national
- nhs branded medicines tranche a - london
- branded medicines - adult influenza
- branded medicines - tranche a london
- nhs branded medicines tranche a - london & sofe & adult influenza national
- nhs framework agreement for branded medicines - tranche
Location
1 buyer
- NHS England Runcorn
28 suppliers
- Roche Products Welwyn Hatfield
- Amgen South Cambridgeshire
- Seqirus Point Market Street Maidenhead
- Biogen Maidenhead
- Teva Wakefield
- Drreddys Laboratories Cambridge
- Orifarm Breakspear Park Hemel Hempstead
- Pfizer Tadworth
- Vifor Pharma Maidenhead
- Accord Whiddon Valley Barnstaple
- Sandoz Western Road Bracknell
- Eli Lilly Basingstoke
- Chugai Pharma Hounslow
- Mylan Hatfield
- Aventis Pharma Reading
- Manx Healthcare Warwick
- Janssen Cilag High Wycombe
- Novo Nordisk Gatwick
- Sun Pharma Uxbridge
- Merck Serono Feltham
- Bayer Reading
- Napp Pharmaceuticals Milton
- Astrazeneca London
- CST Pharma Walsall
- Pharmacosmos Reading
- Thornton & Ross Huddersfield
- Glaxosmithkline London
- Gedeon Richter London
Description
NHS Framework Agreement for Branded Medicines - Tranche A London and South of England and Adult Influenza (National) - 01 September 2025 Offer reference number: CM/PHR/24/5718 CM/PHR/24/5718/01 - NHS Framework Agreement for Branded Medicines - Tranche A for London and South of England. Period of Framework Agreement: 01 September 2025 to 31 August 2027 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months. CM/PHR/24/5718/02 - NHS Framework Agreement for Branded Medicines - Adult Influenza (National). Period of Framework Agreement: 01 September 2025 to 31 August 2026 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months.
Award Detail
1 | Roche Products (None)
|
2 | Amgen (None)
|
3 | Seqirus (Point Market Street Maidenhead)
|
4 | Biogen (Maidenhead)
|
5 | Teva (None)
|
6 | Drreddys Laboratories (Cambridge)
|
7 | Orifarm (Breakspear Park Hemel Hempstead)
|
8 | Pfizer (Tadworth)
|
9 | Vifor Pharma (Maidenhead)
|
10 | Accord (Whiddon Valley Barnstaple)
|
11 | Sandoz (Western Road Bracknell)
|
12 | Eli Lilly (Basingstoke)
|
13 | Chugai Pharma (None)
|
14 | Mylan (Hatfield)
|
15 | Aventis Pharma (Reading)
|
16 | Manx Healthcare (None)
|
17 | Janssen Cilag (High Wycombe)
|
18 | Novo Nordisk (Gatwick)
|
19 | Sun Pharma (Uxbridge)
|
20 | Merck Serono (Feltham)
|
21 | Bayer (Reading)
|
22 | Napp Pharmaceuticals (Milton)
|
23 | Astrazeneca (London)
|
24 | CST Pharma (Walsall)
|
25 | Pharmacosmos (Reading)
|
26 | Thornton & Ross (Huddersfield)
|
27 | Glaxosmithkline (London)
|
28 | Gedeon Richter (London)
|
CPV Codes
- 33600000 - Pharmaceutical products
Indicators
- Contract is suitable for SMEs.
Other Information
CM_PHR_24_5718_01 - Tranche A - London & South of England - Transparency Award Schedule#2 CM_PHR_24_5718_01 - Tranche A - London & South of England - Transparency Award Schedule#2.pdf CM_PHR_24_5718_02 - Tranche A - Adult Influenza National - Transparency Award Schedules#2 CM_PHR_24_5718_02 - Tranche A - Adult Influenza National - Transparency Award Schedules#2.pdf
Reference
- CF-3097600D0O000000rwimUAA
- CF 8a3e4a3c-0b35-41dd-a894-6b259747485a